about
Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment optionsTranslational Rodent Paradigms to Investigate Neuromechanisms Underlying Behaviors Relevant to Amotivation and Altered Reward Processing in SchizophreniaThe Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation.A study of trait anhedonia in non-clinical Chinese samples: evidence from the Chapman Scales for Physical and Social Anhedonia.Impact of negative symptoms on healthcare resource utilization and associated costs in adult outpatients with schizophrenia: a population-based study.The brief negative symptom scale: validation of the German translation and convergent validity with self-rated anhedonia and observer-rated apathy.Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of SchizophreniaA Two-Factor Model Better Explains Heterogeneity in Negative Symptoms: Evidence from the Positive and Negative Syndrome ScaleDissecting negative symptoms in schizophrenia: opportunities for translation into new treatments.Psychometric evaluation of the negative syndrome of schizophrenia.Pharmacological treatment of negative symptoms in schizophrenia.Effort-Based Decision Making: A Novel Approach for Assessing Motivation in Schizophrenia.Managing Negative Symptoms of Schizophrenia: How Far Have We Come?Another view of the history of antipsychotic drug discovery and development.Lessons from MATRICS.Negative Symptom Interventions in Youth at Risk of Psychosis: A Systematic Review and Network Meta-analysis.Negative Symptom Therapeutics.The Concept of Schizophrenia: From Unity to Diversity
P2860
Q22241447-C32F1AF5-26B1-438D-907F-1471DC36C50EQ26801568-697472F7-2F44-42CC-A9F1-2E3C6CB68223Q30547123-992E824A-2475-4105-9D2D-25E47C74A647Q31056281-414D6B4C-8482-48ED-ACCC-2AE1C311B23EQ34109212-243C0FA9-1415-4F12-BA7B-F880A11A78B0Q36201440-3EF26BAF-6786-4794-8E9B-657BC25962A6Q36579938-881E2D01-E07A-4382-9B31-25C505CBAAF1Q36892223-7687A853-F9D3-44FD-B7E0-619C2513945CQ38291334-364BC389-D4DF-4DEE-8543-F270C1939456Q38388526-4086255B-E24C-4424-8D93-92F243F16E68Q38431333-C054BB10-EA7A-4585-A53E-03BC480ED577Q38531872-B332AF7C-E3AD-4768-9345-29FBE7F0770CQ39233330-A3F6E07B-C63C-4B01-972E-1448349CB656Q39569838-E4423A78-48AB-4A6C-87B6-36BCBFDEBE78Q42631017-38EB52C7-83C2-444B-9D43-85A68ACE6A0AQ48001314-1492A192-B1BD-4ACC-A3E3-7424CAD6E3B9Q55433586-EEFC5C36-D931-4F19-A4DE-748E52A0922FQ59052397-B66FCC99-ED57-4EA1-B282-4B814D6DA3B3
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Methodological issues in negative symptom trials
@ast
Methodological issues in negative symptom trials
@en
type
label
Methodological issues in negative symptom trials
@ast
Methodological issues in negative symptom trials
@en
prefLabel
Methodological issues in negative symptom trials
@ast
Methodological issues in negative symptom trials
@en
P2093
P2860
P356
P1476
Methodological issues in negative symptom trials
@en
P2093
A George Awad
David G Daniel
Larry Alphs
Richard S E Keefe
Stephen R Marder
P2860
P304
P356
10.1093/SCHBUL/SBQ161
P407
P577
2011-01-26T00:00:00Z